Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node

Yu Xia, Yu‐Tung Huang, Zheng Liu, Siyuan Song, Yi Wang, Jing LuoFrontiers in Immunology 2025 · DOI

This case report, published in Frontiers in Immunology, details a rare clinical scenario: ovarian cancer that bypassed its usual local spread to manifest as a lump in the patient's armpit (axillary lymph node). By performing the first "panorama" gene profile of this specific metastatic pathway, researchers identified two entirely novel mutations—BTK p.D326E and EPHA5 p.D251E—that may explain how the cancer traveled so far and resisted standard treatments.

TL;DR

Researchers have documented the first comprehensive genomic profile of ovarian cancer metastasized to an axillary lymph node, identifying two novel mutations in the BTK and EPHA5 genes. These findings suggest new molecular mechanisms for distant metastasis and offer potential targets for personalized "oncotherapy" in rare metastatic patterns.

What Problem Does This Paper Address?

Ovarian cancer is notoriously lethal because it is often diagnosed late. Typically, it spreads through the peritoneal cavity (the abdominal lining) to nearby organs. Metastasis to the axillary lymph nodes—located in the armpit—is extremely rare.

When a patient presents with an axillary mass, clinicians almost always suspect "occult" breast cancer. This leads to a high risk of misdiagnosis. Furthermore, the genetic "why" behind this unusual migration is poorly understood. This paper aims to bridge that gap by using Next-Generation Sequencing (NGS) to find the specific genetic drivers that allow ovarian cancer to behave like a distant-traveling systemic disease.

Methods

The researchers employed a multi-modal diagnostic approach:

  • Clinical Imaging: A battery of tests including ultrasound, mammography, MRI, and PET-CT to locate the primary tumor and metastatic sites.
  • Histopathology & IHC: Tissue biopsies were analyzed using Immunohistochemistry (IHC). Markers like WT-1, PAX8, and p53 were used to confirm the tumor was ovarian in origin, rather than breast cancer.
  • Genomic Profiling (NGS): The team used a targeted 437-gene panel to sequence the tumor’s DNA and RNA. They looked for Single Nucleotide Variations (SNVs), Copy Number Variations (CNVs), and assessed the Tumor Mutational Burden (TMB) and Homologous Recombination Deficiency (HRD) score.

Datasets

As a case report, the primary "dataset" is the genomic and clinical data from a single 56-year-old female patient. To confirm the novelty of their findings, the authors cross-referenced the identified mutations against established cancer databases, including COSMIC and ClinVar.

Key Insights and Ideas

  • The Diagnostic "Switch": While imaging initially suggested breast cancer, IHC was the "aha" moment. The tumor was positive for CK7, ER, and WT-1, but negative for breast-specific markers, confirming it was high-grade serous ovarian carcinoma (HGSOC).
  • BTK’s New Role: BTK (Bruton’s tyrosine kinase) is a famous target in blood cancers like leukemia. Finding a novel mutation (p.D326E) in a solid tumor like ovarian cancer is significant. The authors suggest this mutation might help the tumor evade the immune system or survive in the bloodstream.
  • EPHA5 and "Detachment": The novel EPHA5 p.D251E mutation occurs in the extracellular domain of the receptor. The authors hypothesize that this mutation weakens intercellular adhesion, essentially making the cancer cells "slippery" enough to detach and migrate to distant lymph nodes.
  • Precision Medicine in Action: The NGS also found a BRCA2 frameshift mutation and a high HRD score. This allowed the clinical team to pivot the treatment plan toward PARP inhibitors and bevacizumab, which are specifically effective for tumors with these genetic signatures.

Key Results

  • Novelty: Discovery of two previously unreported missense mutations: BTK (p.D326E) and EPHA5 (p.D251E).
  • Genomic Landscape: The tumor showed high genomic instability, including mutations in TP53 and ROS1, and amplifications in PIK3R1.
  • Clinical Success: Following surgery and a chemotherapy regimen adjusted based on the genomic findings (paclitaxel, carboplatin, and bevacizumab), the patient’s tumor markers (CA125) declined significantly, and follow-up CT scans showed a marked decrease in the size of the axillary lymph nodes within four months.

Limitations and Future Work

The authors acknowledge several limitations:

  • Follow-up Duration: The study only covers a few months post-treatment; long-term survival and recurrence patterns remain unknown.
  • Sample Size: As a single-case study, these findings cannot yet be generalized to all patients with rare ovarian metastases.
  • Functional Validation: While the mutations are novel, the paper does not include in vitro (cell culture) or animal model experiments to definitively prove that these specific mutations caused the metastasis or drug resistance.

Future research is needed to screen more patients for these mutations and to test whether BTK inhibitors—already used in hematology—could be repurposed for ovarian cancer patients carrying the p.D326E variant.

Summary updated

Abstract

This is the first report on the panorama gene profile of ovarian cancer metastasis to axillary lymph node and we found two novel mutations (BTK pD326E and EPHA5 pD251E). This study unraveled the potential mechanism of genetic mutation for tumor metabolism, drug resistance, and metastasis.
BibTeX
@inproceedings{xia2025case,
  author = {Yu Xia and Yu‐Tung Huang and Zheng Liu and Siyuan Song and Yi Wang and Jing Luo},
  title = {{Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1548102},
}
Figure